Resveratrol (research-only chemoprevention candidate — NOT standard-of-care)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-RESVERATROL-RESEARCH-ONLY |
|---|---|
| Type | Drug |
| Aliases | 3,5,4'-trihydroxy-trans-stilbeneResveratrol research-onlytrans-Resveratrolvarious OTC supplements — Longevinex, Resvitrol, Resveratrol extractРесвератрол (дослідницький кандидат — НЕ стандарт допомоги) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BREAST-2025 SRC-WCRF-AICR-CUP-2018 |
Drug Facts
| Class | Polyphenol / stilbenoid — dietary supplement (food-grade phytochemical from grape skins, peanuts, berries) |
|---|---|
| Mechanism | Naturally occurring stilbenoid polyphenol; activates SIRT1 (NAD+- dependent deacetylase) and modulates AMPK signaling, mTOR, NF-κB, and estrogen-receptor pathways in preclinical models. Cancer- prevention rationale (preclinical): induces cell-cycle arrest and apoptosis in tumor cell lines, inhibits inflammation, suppresses COX-2, modulates ER signaling. Animal models show reduction in chemically induced skin, mammary, colorectal, and prostate tumors. CRITICAL LIMITATION FOR CLINICAL TRANSLATION: oral bioavailability is ~1% (extensive sulfation/glucuronidation), and human plasma concentrations achieved with supplements are 10-100× lower than active concentrations in preclinical models. No clinical trial of any size has demonstrated cancer-preventive efficacy in humans. |
| Typical dosing | RESEARCH-ONLY context — NO accepted clinical-use dose: Trial-level dosing ranged 150 mg to 5 g/day in small pilot studies (mostly metabolic / cardiovascular endpoints, not oncology). Most commercial supplements 250-500 mg/day standardized to trans-resveratrol; no evidence this dose achieves meaningful systemic exposure due to extensive first-pass metabolism. No regulatory body recommends resveratrol for cancer chemoprevention. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 chemoprevention-workstream authoring (batch 2); pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. RESVERATROL IS NOT STANDARD-OF-CARE CHEMOPREVENTION (research-only context). Preclinical signal is well-documented but clinical translation is fundamentally limited by very poor bioavailability. No completed phase-III primary-prevention oncology RCT exists. SRT501 myeloma trial (Popat 2013) stopped early due to nephrotoxicity in patients who received 5 g/d for 20 days. NCCN / USPSTF / WCRF-AICR / ASCO — no recommendation for resveratrol supplementation for cancer prevention or in cancer survivorship. EXPLICIT CAUTION: phytoestrogen activity → avoid in ER+ breast-cancer survivors on adjuvant tamoxifen or AI (theoretical antagonism / interference). ENGINE MUST NOT recommend resveratrol for cancer prevention; entity exists for catalog completeness and for explicit counseling away from OTC chemoprevention marketing. Product quality and standardization are highly variable. No primary resveratrol prevention RCT exists; cited sources cover the umbrella WCRF + NCCN Breast guidelines (which do NOT include resveratrol).
Used By
No reverse references found in the YAML corpus.